0
Lung Cancer: Lung Cancer II |

Study on Attenuating Angiogenesis of Pulmonary Malignant Tumor by Targeting FAK Both in vivo and in vitro. FREE TO VIEW

Shun Liu; Lan Pu; Yi Huang; Feng Wu; Ling Gong; Lan Zhu; Qian Chen; Chuan Huang
Author and Funding Information

The Institute of Respiratory Diseases in Zunyi City, The First People's Hospital of Zunyi City, Zunyi, China


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;149(4_S):A311. doi:10.1016/j.chest.2016.02.324
Text Size: A A A
Published online

SESSION TITLE: Lung Cancer II

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM

PURPOSE: To investigate the role of Focal Adhesion Kinase (FAK) in angiogenesis of pulmonary malignant tumor in vivo and in vitro.

METHODS: We detected the expression of FAK in human umbilical vein endothelial cells (HUVECs), and we used TAE226, FAK siRNA and analyzed their inhibitory effects on HUVECs in vitro. Tumor xenografts in nude mice were used to examine the in vivo activity of TAE226 and FAK siRNA.

RESULTS: Fluorescent quantitative PCR revealed that the expression of FAK was much higher in HUVECs than that of Y-MESO-14 and NCI-H290TAE226 and FAK siRNA inhibited VEGF-induced FAK mRNA expression. Western blot analysis indicated that FAK siRNA inhibited VEGF-induced total FAK and TAE226 inhibited VEGF-induced phosphorylation of FAK in HUVEC. TAE226 and FAK siRNA significantly inhibits VEGF-induced HUVEC proliferation, migration, and tube formation. TAE226 induces the apoptosis of HUVEC. The antiangiogenic effect by CD31 immunohistochemical staining indicated that TAE226 inhibited tumorigenesis by targeting angiogenesis.

CONCLUSIONS: It is clarified that FAK not merely is a critical factor of angiogenesis in chest malignant tumor, but also involves in the development and progression of malignant tumors. And it would provide an extremely novel potential targets for pulmonary malignant tumor therapy

CLINICAL IMPLICATIONS: This study would provide an extremely novel potential targets for pulmonary malignant tumor therapy.

DISCLOSURE: The following authors have nothing to disclose: Shun Liu, Lan Pu, Yi Huang, Feng Wu, Ling Gong, Lan Zhu, Qian Chen, Chuan Huang

No Product/Research Disclosure Information


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543